Do you routinely offer AR-v7 testing to determine whether to treat with chemotherapy versus enzalutamide or abiraterone in metastatic castration resistant prostate cancer?

The short answer is no, not yet, and not outside of a research study. AR-V7 testing using a CLIA approved circulating tumor cell (CTC) assay, either Qiagen-Hopkins using the Adnatest RT-PCR platform or the EPIC-Genomic Health protein assay, appear very promising as negative predictors of the clinica...

Our perspective is clearly biased, but we are routinely doing AR-V7 testing in the post-Abi or post-Enza patients who have not yet received taxane therapy to help make the choice between second AR-directed agent versus taxane agent versus clinical trial participation. A recent paper by Scher HI et a...